Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: April 2011

Chapter 44 - Positive inotropic drugs

Related content

Powered by UNSILO


1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20: 248–54.
2. Komamura K, Shannon RP, Ihara T, et al. Exhaustion of Frank–Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993; 265: H1119–H1131.
3. Armstrong PW, Moe GW. Medical advances in the treatment of congestive heart failure. Circulation 1993; 88: 2941–52.
4. Toller WG, Stranz C. Levosimendan, a new inotropic and vasodilator agent. Anesthesiology 2006; 104: 556–69.
5. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol 1997; 79: 794–8.
6. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE for implantation of cardiac pacemakers and antiarrhythmia devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51: e1–e62.
7. Royster RL, Butterworth JF, Prielipp RC, et al. A randomized, placebo-controlled evaluation of calcium chloride and epinephrine for inotropic support after emergence from cardiopulmonary bypass. Anesth Analg 1992; 74: 3–13.
8. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997; 336: 525–33.
9. Hauptman PJ, Kelly RA. Digitalis. Circulation 1999; 99: 1265–70.
10. Post SR, Hammond HK, Insel PA. Beta-adrenergic receptors and receptor signaling in heart failure. Annu Rev Pharmacol Toxicol 1999; 39: 343–60.
11. Booth JV, Landolfo KP, Chesnut LC, et al. Acute depression of myocardial beta-adrenergic receptor signaling during cardiopulmonary bypass. Impairment of the adenylyl cyclase moiety. Duke Heart Center Perioperative Desensitization Group. Anesthesiology 1998; 89: 602–11.
12. Leenen FH, Chan YK, Smith DL, et al. Epinephrine and left ventricular function in humans: effects of beta-1 vs nonselective beta blockade. Clin Pharmacol Ther 1988; 43: 519–28.
13. Butterworth JF, Prielipp RC, Royster RL, et al. Dobutamine increases heart rate more than epinephrine in patients recovering from aortocoronary bypass surgery. J Cardiothorac Vasc Anesth 1992; 6: 535–41.
14. Fellahi JL, Parienti JJ, Hanouz J, et al. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology 2008; 108: 979–87.
15. MacGregor DA, Smith TE, Prielipp RC, et al. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 2000; 92: 338–46.
16. Griffin MJ, Hines RL. Management of perioperative ventricular dysfunction. J Cardiothorac Vasc Anesth 2001; 15: 90–106.
17. Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510–24.
18. Fitton A, Benfield P. Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency. Drugs 1990; 39: 308–30.
19. MacGregor DA, Butterworth JF, Zaloga GP, et al. Hemodynamic and renal effects of dopexamine and dobutamine in patients with reduced cardiac output following coronary artery bypass grafting. Chest 1994; 106: 835–41.
20. Berendes E, Mollhoff T, Van Aken H, et al. Effects of dopexamine on creatinine clearance, systemic inflammation, and splanchnic oxygenation in patients undergoing coronary artery bypass grafting. Anesth Analg 1997; 84: 950–7.
21. Binkley PF, Van Fossen DB, Nunziata E, et al. Influence of positive inotropic therapy on pulsatile hydraulic load and ventricular-vascular coupling in congestive heart failure. J Am Coll Cardiol 1990; 15: 1127–35.
22. Keren G, Laniado S, Sonnenblick EH, et al. Dynamics of functional mitral regurgitation during dobutamine therapy in patients with severe congestive heart failure: a Doppler echocardiograhic study. Am Heart J 1989; 118: 748–54.
23. Aronson S, Dupont F, Savage R, et al. Changes in regional myocardial function after coronary artery bypass are predicted by intraoperative low-dose dobutamine echocardiography. Anesthesiology 2000; 93: 685–92.
24. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57–64.
25. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared to dobutamine in severe low-output heart failure (the LIDO study): a randomised double blind trial. Lancet 2002; 360: 196–202.
26. Tinker JH, Tarhan S, White RD, et al. Dobutamine for inotropic support during emergence from cardiopulmonary bypass. Anesthesiology 1976; 44: 281–6.
27. Movsesian MA, Smith CJ, Krall J, et al. Sarcoplasmic reticulum-associated cyclic adenosine 5′-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 1991; 88: 15–19.
28. Kajimoto K, Hagiwara N, Kasanuki H, et al. Contribution of phosphodiesterase isozymes to the regulation of L-type calcium current in human cardiac myocytes. Br J Pharmacol 1997; 121: 1549–56.
29. Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res 1996; 79: 1059–63.
30. Doolan LA, Jones EF, Kalman J, et al. A placebo-controlled trial verifying the efficacy of milrinone in weaning high-risk patients from cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 37–41.
31. Chen EP, Bittner HB, Davis RD, et al. Hemodynamic and inotropic effects of milrinone after heart transplantation in the setting of recipient pulmonary hypertension. J Heart Lung Transplant 1998; 17: 669–78.
32. Konstam MA, Cody RJ. Short-term use of intravenous milrinone for heart failure. Am J Cardiol 1995; 75: 822–6.
33. Tisdale JE, Patel R, Webb CR, et al. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995; 38: 167–80.
34. Hayashida N, Tomoeda H, Oda T, et al. Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Ann Thorac Surg 1999; 68: 1661–7.
35. Cracowski JL, Stanke-Labesque F, Chavanon O, et al. Vasorelaxant actions of enoximone, dobutamine, and the combination on human arterial coronary bypass grafts. J Cardiovasc Pharmacol 1999; 34: 741–8.
36. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 1991; 325: 1468–75.
37. Lowes BD, Higginbotham M, Petrovich L, et al. Low dose enoximone improves exercise capacity in chronic heart failure. Enoximone Study Group. J Am Coll Cardiol 2000; 36: 501–8.
38. Shakar SF, Abraham WT, Gilbert EM, et al. Combined oral positive inotropic and beta-blocker therapy for the treatment of refractory Class IV heart failure. J Am Coll Cardiol 1998; 31: 1336–40.
39. Kikura M, Lee MK, Safon RA, et al. The effects of milrinone on platelets in patients undergoing cardiac surgery. Anesth Analg 1995; 81: 44–8.
40. Rathmell JP, Prielipp RC, Butterworth JF, et al. A multicenter, randomized, blind comparison of amrinone and milrinone after elective cardiac surgery. Anesth Analg 1998; 86: 683–90.
41. Feneck RO. Intravenous milrinone following cardiac surgery: II. Influence of baseline hemodynamics and patient factors on therapeutic response. The European Milrinone Multicentre Trial Group. J Cardiothorac Vasc Anesth 1992; 6: 563–7.
42. Butterworth JF, Hines RL, Royster RL, et al. A pharmacokinetic and pharmacodynamic evaluation of milrinone in adults undergoing cardiac surgery. Anesth Analg 1995; 81: 783–92.
43. Prielipp RC, MacGregor DA, Butterworth JF, et al. Pharmacodynamics and pharmacokinetics of milrinone administration to increase oxygen delivery in critically ill patients. Chest 1996; 109: 1291–301.
44. Dupuis JY, Bondy R, Cattran C, et al. Amrinone and dobutamine as primary treatment of low cardiac output syndrome following coronary artery surgery: a comparison of their effects on hemodynamics and outcome. J Cardiothorac Vasc Anesth 1992; 6: 542–53.
45. Butterworth JF, Royster RL, Prielipp RC, et al. Amrinone in cardiac surgical patients with left-ventricular dysfunction: a prospective, randomized placebo-controlled trial. Chest 1993; 104: 1660–7.
46. Royster RL, Butterworth JF, Prielipp RC, et al. Combined inotropic effects of amrinone and epinephrine after cardiopulmonary bypass in humans. Anesth Analg 1993; 77: 662–72.
47. Tachibana H, Cheng HJ, Ukai T, et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005; 288: H914–22.
48. Scoote M, Williams AJ. Myocardial calcium signaling and arrhythmia pathogenesis. Biochem Biophys Res Comm 2004; 322: 1286–9.
49. Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384–416.
50. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target for a novel calcium sensitzing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859–66.
51. Haikala H, Levijoki J, Linden IB. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension. J Mol Cell Cardiol 1995; 27: 2155–65.
52. Masutani S, Cheng HJ, Hytilla-Hopponen M, et al. Orally available levosimendan dose-related positive inotropic and lusitropic effect in conscious chronically instrumented normal and heart failure dogs. J Pharmacol Exp Ther 2008; 325: 236–47.
53. Soei LK, Sassen LMA, Fan DS, et al. Myofibrillar Ca2+ sensitization predominantly enhances function and mechanical efficiency of stunned myocardium. Circulation 1994; 90: 959–69.
54. Haikala H, Nissinen E, Etemadzadeh E, et al. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 1995; 25: 794–801.
55. Givertz MM, Andreou C, Conrad CH, et al. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation-frequency relationships. Circulation 2007; 115: 1218–24.
56. Dernillis J, Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study. Chest 2005; 128: 2633–9.
57. Pataricza J, Krassoi I, Hohn J, et al. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery. Cardiovasc Drugs Ther 2003; 17: 115–21.
58. Bowman P, Haikala H, Paul RJ. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 288:316–325, 1999.
59. Haikala H, Linden IB. Mechanisms of action of calcium-sensitizing drugs. J Cardiovasc Pharmacol 1995; 26: S10–S19.
60. Yokoshiki H, Katsube Y, Sunagawa M, et al. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 1997; 283: 375–83.
61. Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial KATP channel opener. Eur J Pharmacol 2001; 428: 311–14.
62. Kersten JR, Montgomery MW, Pagel PS, et al. Levosimendan, a positive inotropic agent, decreases myocardial infarct size via activation of KATP channels. Anesth Analg 2000; 90: 5–11.
63. Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial infarction. J Am Coll Cardiol 2004; 43: 2177–82.
64. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ. Utility of levosimendan, a new calcium sensitizing agent, in the treatment of cardiogenic shock due to myocardial stunning in patients with ST-elevation myocardial infarction: a series of cases. J Clin Pharmacol 2005; 45: 704–8.
65. Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting – a pilot study. Br J Anaesth 2006; 96: 694–700.
66. Remme WJ, Wiesfeld ACP, Look MP, et al. Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 1989; 14:S41–S44.
67. Thormann J, Kramer W, Schlepper M. Hemodynamic and myocardial energetic changes induced by the new cardiotonic agent, AR-L 115, in patients with coronary artery disease. Am Heart J 1982; 104: 1294–302.
68. Todaka K, Wang J, Yi GH, et al. Effects of levosimendan on myocardial contractility and oxygen consumption. J Pharmacol Exp Ther 1996; 279: 120–7.
69. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 1992; 85: 942–9.
70. Lubsen J, Just H, Hjalmarsson AC, et al. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. Heart 1996; 76: 223–31.
71. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903–12.
72. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222–7.
73. Moiseyev VS, Poder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 23: 1422–32.
74. Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a controlled randomized clinical trial. Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. JAMA 2002; 287: 1578–80.
75. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Ferrer-Hita JJ, et al. Cardiogenic shock after percutaneous coronary intervention: effects of levosimendan compared with dobutamine on haemodynamics. Eur J Heart Fail 2006; 8: 723–8.
76. Adamopoulos S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98: 102–6.
77. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19: 660–8.
78. Labriola C, Siro-Brigiani M, Carrata F, et al. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery. Int J Clin Pharmacol Ther 2004; 42: 204–11.
79. Siirila-Waris K, Suojaranta-Ylinen R, Harjola VP. Levosimendan in cardiac surgery. J Cardiothorac Vasc Anesth 2005; 19: 345–9.
80. Barisin S, Husedzinovic I, Sonicki Z, et al. Levosimendan in off-pump coronary artery bypass: a four-times masked controlled study. J Cardiovasc Pharmacol 2004; 44: 703–8.
81. De Hert SG, Lorsomradee S, Cromheecke S, et al. Effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104: 766–73.
82. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81–6.
83. Hamilton MA. Prevalence and clinical implications of abnormal thyroid hormone metabolism in advanced heart failure. Ann Thorac Surg 1993; 56: S48–S52.
84. Jamali IN, Pagel PS, Hettrick DA, et al. Positive inotropic and lusitropic effects of triiodothyronine in conscious dogs with pacing-induced cardiomyopathy. Anesthesiology 1997; 87: 102–9.
85. Han J, Leem C, So I, et al. Effects of thyroid hormone on the calcium current and isoprenaline-induced background current in rabbit ventricular myocytes. J Mol Cell Cardiol 1994; 26: 925–35.
86. Ririe DG, Butterworth JF, Royster RL, et al. Triiodothyronine increases contractility independent of beta-adrenergic receptors or stimulation of cyclic-3’,5’-adenosine monophosphate. Anesthesiology 1995; 82: 1004–12.
87. Kadletz M, Mullen PG, Ding M, et al. Effect of triiodothyronine on postishemic myocardial function in the isolated heart. Ann Thorac Surg 1994; 57: 657–62.
88. Mahaffey KW, Raya TE, Pennock GD, et al. Left ventricular performance and remodeling in rabbits after myocardial infarction. Effects of a thyroid hormone analogue. Circulation 1995; 91: 794–801.
89. Moruzzi P, Doria E, Agostoni PG, et al. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol 1994; 73: 374–8.
90. Chu SH, Huang TS, Hsu RB, et al. Thyroid hormone changes after cardiovascular surgery and clinical implications. Ann Thorac Surg 1991; 52: 791–6.
91. Novitzky D, Cooper DK, Human PA, et al. Triiodothyronine therapy for heart donor and recipient. J Heart Transplant 1988; 7: 370–6.
92. Dyke CM, Ding M, Abd-Elfattah AS, et al. Effects of triiodothyronine supplementation after myocardial ischemia. Ann Thorac Surg 1993; 56: 215–22.
93. Bennett-Guerrero E, Jimenez JL, White WD, et al. Cardiovascular effects of intravenous triiodothyronine in patients undergoing coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled trial. Duke T3 study group. JAMA 1996; 275: 687–92.
94. Prielipp RC, MacGregor DA, Royster RL, et al. Dobutamine antagonizes epinephrine's biochemical and cardiotonic effects: results of an in vitro model using human lymphocytes and a clinical study in patients recovering from cardiac surgery. Anesthesiology 1998; 89: 49–57.
95. Abernethy WB, Butterworth JF, Prielipp RC, et al. Calcium entry attenuates adenylyl cyclase activity: a possible mechanism for calcium-induced catecholamine resistance. Chest 1995; 107: 1420–5.
96. McGough MF, Pagel PS, Lowe D, et al. Levosimendan potentiates the inotropic actions of dopamine in conscious dogs. J Cardiovasc Pharmacol 1996; 28: 36–47.